132P - Real world treatment patterns and outcomes for mNSCLC patients receiving second and third-line therapy in Germany

Date 07 May 2017
Event ELCC 2017
Session Poster Display Session
Topics Thoracic malignancies
Non-small-cell lung cancer
Presenter Ning Yu
Citation Annals of Oncology (2017) 28 (suppl_2): ii28-ii51. 10.1093/annonc/mdx091
Authors N. Yu1, I. Reyes-Rivera2, J. Hipp3, M. Zou4, N. Pillai4, S. Hammerschmidt5
  • 1Roche Products Ltd, AL71TW - Welwyn/GB
  • 2F. Hoffmann-La Roche, Basel/CH
  • 3Roche Pharma AG, Grenzach-Wyhlen/DE
  • 4QuintilesIMS, Basel/CH
  • 5Klinikum Chemnitz gGmbH, Chemnitz/DE

Abstract

Background

Metastatic non-small cell lung cancer (mNSCLC) is the leading cause of cancer death worldwide. Recent approvals of targeted therapies, especially immunotherapies, may change the treatment landscape, but little is known about their real-world impact. This study (MO39087) assessed real world treatment patterns and outcomes of patients (pts) receiving second- (2L) and/or third-line (3L) therapy for mNSCLC in Germany.

Methods

A retrospective, non-interventional, observational study was performed with secondary data from the German Oncology Network of outpatient treatment centres. Participating office-based oncologists across Germany provided de-identified longitudinal patient-level data via electronic case report forms for mNSCLC pts. Pts were followed from start of 2L and 3L (index dates) until death/loss to follow up. Pt characteristics and treatment patterns were described. Overall survival (OS) and progression-free survival (PFS) from index dates were calculated using the Kaplan-Meier method.

Results

Of pts diagnosed between Jan 2007–Jul 2016, 340 and 123 pts started 2L and 3L therapy, respectively. Of these, 56% in 2L and 59% in 3L were treated in 2014 or later. The top 3 regimens in 2L were monotherapies of docetaxel (n = 55, 16%), vinorelbine (n = 41, 12%) and pemetrexed (n = 40, 12%). In 3L, the top 3 regimens were monotherapies of docetaxel (n = 19, 15%), vinorelbine (n = 17, 14%) and gemcitabine (n = 11, 9%). Since 2014, an increase in pts on targeted therapies was seen in 2L (25%, 47/192, n = 15 for immunotherapy) vs before 2014 (14%, 20/148). The same trend was also seen in 3L (since 2014, 25%, 18/72, n = 9 for immunotherapy; before 2014, 16%, 8/51). Median OS and PFS was 8 mths (95% CI 6.6–8.9) and 5 mths (95% CI 4.2–5.3) for 2L, and 9 mths (95% CI 6.4–10.3) and 4 mths (95% CI 3.0–5.9) for 3L.

Conclusions

Despite a trend of increased uptake of 2/3L targeted therapies since 2014, prescription levels were still low and single agent chemotherapy still dominates. Given the small number of pts and short observation time, especially for immunotherapy, further studies will be needed when a broader uptake of immunotherapy is expected, to fully assess the impact on treatment patterns and survival.

Clinical trial identification

M039087

Legal entity responsible for the study

Roche Pharmaceutical

Funding

Roche Pharmaceutical

Disclosure

N. Yu: Roche employee. I. Reyes-Rivera: Employee: F. Hoffmann-La Roche Ltd., Stock ownership: F. Hoffmann-La Roche Ltd. J. Hipp: Employee: Roche Pharma AG, and Stock ownership: F. Hoffmann La-Roche. M. Zou: Corporate-sponsored research by Roche. S. Hammerschmidt: Advisory board or board of directors: Astra Zeneca, Boehringer-Ingelheim, BMS, Novartis, Pfizer, Roche. All other authors have declared no conflicts of interest.